Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab biosimilar (Inbiopro Solutions Pvt Ltd.), 曲妥珠单抗生物类似药(Inbiopro Solutions Pvt Ltd.), IBPM 002BZ + [2] |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Clinical | India | - | |
Renal Cell Carcinoma | Clinical | India | - | |
Small Cell Lung Cancer | Clinical | India | - |